Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week phase 3 randomized double-blind placebo-controlled trial of etrasimod in moderately to severely active ulcerative colitis
MOH_2019-08-21_007360Phase 3Recruiting
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrasimod with Placebo (2 arms). Started Jun 2019; status: recruiting.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2019-08-21_007360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-21_007360.